Related Experiment Videos
Molecular diagnosis in LGMD2A: mutation analysis or protein testing?
M Fanin1, L Fulizio, A C Nascimbeni
1Department of Neurosciences, University of Padova, Italy. marina.fanin@unipd.it
Human Mutation
|June 29, 2004
Summary
Limb girdle muscular dystrophy type 2A diagnosis can now rely on calpain-3 protein analysis. Complete protein deficiency strongly indicates LGMD2A, aiding genetic counseling for patients with limb girdle muscular dystrophy.
Area of Science:
- Biochemistry
- Genetics
- Neurology
Background:
- Limb girdle muscular dystrophy type 2A (LGMD2A) is caused by mutations in the CAPN3 gene.
- Diagnosis has shifted towards biochemical assays for calpain-3 protein, but sensitivity and specificity need evaluation.
- Genotype-protein-phenotype correlations in LGMD2A require further investigation.
Purpose of the Study:
- Correlate protein and molecular data in a large LGMD2A patient cohort.
- Evaluate the diagnostic utility of calpain-3 protein analysis.
- Identify key mutation hotspots in the CAPN3 gene.
Main Methods:
- Immunoblot screening for calpain-3 protein in 548 patients.
- CAPN3 gene mutation analysis using SSCP, DHPLC, ARMS-PCR, and sequencing.
- Statistical analysis to determine the probability of LGMD2A based on protein levels.
Main Results:
- Identified 58 LGMD2A patients; 80% showed protein deficiency, 20% had normal calpain-3 levels.
- Complete calpain-3 deficiency yielded an 84% probability of LGMD2A.
- Detected 37 CAPN3 mutations, 10 novel; 87% of mutations located in seven specific exons.
Conclusions:
- Calpain-3 protein analysis is a valuable diagnostic tool for LGMD2A, especially in cases of complete deficiency.
- Protein level data can significantly aid genetic counseling when molecular data is pending.
- Focusing molecular analysis on specific CAPN3 exons can improve diagnostic efficiency for LGMD2A.